

July 2018

Dear Healthcare Professionals,

As you know, Pfizer Injectables has been working to address ongoing supply shortages, including some products that are used in critical situations. Since shortages began, we're not only working to resolve current issues, we are working to minimize the potential for future shortages by investing \$800 million in capital in our injectables manufacturing network by the end of 2018. In addition, an incremental \$1.3 to \$1.4 billion investment will be made in these important facilities over the next 5 years.

We deeply regret the issues the shortages have caused you and your patients. From the conversations we've had with many hospitals and healthcare institutions, we know the impact of shortages is far-reaching. We want to assure you that it is our number one priority at Pfizer Injectables to resolve and restore supply as soon as possible, while providing timely and transparent communication.

PRIORITIZING MEDICALLY NECESSARY DRUGS

We are prioritizing the manufacture of medically necessary products and increasing production at key manufacturing plants as part of our supply recovery effort. Pfizer is also working with the FDA to extend the time that medically necessary products in short supply can be used.

FIXING THE CAUSES OF SHORTAGES

The current supply shortages have been caused by a combination of factors. To date, we have successfully resolved our distribution and system integration issues. We've also had several products come off the shortages list in 2018. While Pfizer continues to make progress on our recovery plan, manufacturing challenges are ongoing and will extend into 2019.

Some areas of progress to note:

- Production line transfers are underway to help bring alternate approved manufacturing capabilities and sources on line to help expedite recovery efforts
- Staffing increases in all areas of manufacturing sites including quality, labs, manufacturing, production, batch release, investigations, and management
- Prioritizing wholesalers and distribution channel deliveries to reach broad customer segments more quickly
- Qualifying additional alternative third-party suppliers who meet Pfizer quality standards for components and finished goods availability
- Three replacement autoclaves will be fully operational in 2018. These autoclaves will be used to sterilize manufacturing equipment as it is brought into the aseptic core. In addition, new autoclaves are being installed and are projected for operation in 2019

We are also working on a plan to increase safety stock so we have additional inventory to help mitigate future shortages. We are focused on organizational preparedness and communications infrastructure to communicate quickly and thoroughly, especially in times of supply shortages.

COMMITTED TO SHARING RECOVERY UPDATES

Pfizer is working closely with the FDA regarding the drug shortages and continues to provide information to the American Society of Health-System Pharmacists (ASHP), as well as to other professional groups. We also have a supply recovery-specific website, PfizerInjectablesSupply.com, where you can access real-time product updates. Talk to your Pfizer Representative to learn how you can easily sign up for a personalized availability report with products pertaining to your institution.

Despite our supply challenges, we remain dedicated to the injectables business and to helping you care for your patients. We are committed to helping you stay informed with the latest information about our recovery, so you can plan patient care accordingly.

Sincerely,



Navin Katyal
General Manager, Pfizer Injectables—US Pfizer Essential Health